Older, younger patients with metastatic pancreatic cancer have similar survival
the ONA take:
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy and receive fewer agents yet have similar overall survival compared with younger patients with metastatic disease, according to a recent study published online ahead of print in the Journal of Geriatric Oncology.
For the study, researchers at Fox Chase Cancer Center in Philadelphia, PA, sought to compare patterns of care and outcomes of patients with metastatic pancreatic cancer who are less than 65 years of age with those older than 65 years of age treated at their institution.
The researchers analyzed the medical records of 579 patients who were treated between 2000 and 2010. Results showed that patients older than 65 years were less likely to receive any chemotherapy for their cancer. In addition, those over 65 who were treated were less likely to receive more than 1 agent.
Researchers found that survival was comparable between the two cohorts. In both groups, a higher number of treatment agents and lung metastatases was associated with longer overall survival, while liver metastates were associated with worse survival.
The findings suggest that older patients with metastatic pancreatic cancer with good performance status should be encouraged to enroll onto clinical trials.
Older patients metastatic pancreatic cancer are less likely to receive chemotherapy compared with younger patients with metastatic disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|